Abzena & Regeneron’s Journal Article on Potent Rifampicin Derivatives

16th November 2023

Abzena & Regeneron published a recent scientific journal article entitled, “Potent Rifampicin derivatives can clear MRSA infections at single low doses when concomitantly dosed with Vancomycin”.

Click here to access the journal publication

Journal Abstract
For a number of years, antimicrobial resistance (AMR) has been a critical issue for humanity. Drug discovery efforts have been very limited and the spread of bacterial pathogens has over-run our traditional arsenal of antibiotics. Bacteria can involve to evade compounds that can halt their rapid growth. The authors have discovered a potent macrocycle derivative that when dosed concomitantly with the standard of care (SOC) antibiotic vancomycin, can clear methicillin resistant Staphylococcus aureus (MRSA) infections. In addition, we have probed the lead compounds in Salmonella Typhimurium bacterial strains. In vitro, in vivo, and ADME data have been included to stress the virtues of this new antibiotic.

Solutions for improving early phase development

At Abzena, we develop novel and improve existing synthetic routes for complex chemicals, cytotoxins, payloads, linkers, HPAPI, biopolymers, and nanoparticles. We design, evaluate, and execute state-of-the-art synthetic strategies to deliver quality molecules with chiral integrity.  Our extensive scientific capabilities and innovative solutions are designed to reduce risk and give your program the best chance of clinical and commercial success.

We offer product development and formulation programs to accelerate your timelines by leveraging our comprehensive in-house capabilities, technologies, and knowledge to deliver processes tailored to your molecule of interest.

We ensure the purity and integrity of your products by offering an extensive range of capabilities in the Analytical Method Development (AMD) and QC departments.

We utilize quality by design (QbD) principles and follow ICH Product Lifecycle guidelines to develop processes for manufacturing at toxicology, clinical, and commercial scale. Our knowledge of cGMP manufacturing enables us to successfully transfer existing processes into our facilities or develop a new innovative process, when needed, to meet your program needs.

For more information about Abzena’s extensive chemistry capabilities visit: Chemistry | Bioconjugates & Chemistry | Chemistry Capabilities (abzena.com)